The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

June 14, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
racorn/shutterstock.com

racorn/shutterstock.com

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy.

You Might Also Like
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
Explore This Issue
June 2017
Also By This Author
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?

“It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of Medicine, vice chair of internal medicine, and chief of the Division of Rheumatology at the University of Nebraska Medical Center in Omaha. “There are several areas where it is problematic and makes no sense at all.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Soaring Ever Higher

Healthcare costs keep rising. The Centers for Medicare and Medicaid Services (CMS) estimates that U.S. prescription drug spending grew 9% in 2015 to $324.6 billion, and out-of-pocket spending by patients for healthcare costs grew 2.6% to $338.1 billion in the same year. The CMS projects that total national health expenditures will soar 5.6% each year between 2016 and 2025.1

While acknowledging that biologics—an essential treatment for many patients with inflammatory diseases, such as rheumatoid arthritis (RA)—are expensive to produce compared with synthetic drugs, their costs seem to be rising dramatically, says Dr. O’Dell.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“My patients used to be able to use a TNF [tumor necrosis factor] inhibitor for about $8,000–10,000 a year, but the cost is now $50,000 a year—less than 20 years later,” he says. Drug pricing is often murky, but one retail drug price comparison website, www.goodrx.com, lists prices for one carton of four self-injectable doses of etanercept (Enbrel) ranging from $4,539–4,788. The recommended dosage for adults with RA generally is one injection per week, so the retail price for a year’s supply of this drug is approximately $54,468. What patients actually pay out of pocket for their medications depends on their individual insurance plans, as well as potential discounts, coupons and copay assistance programs that some manufacturers offer. “There is not much transparency in what the costs really are—or what the drugs even cost to produce—and that is another part of the issue.”

Will Biosimilars Help?

Biosimilars, biologic products designed to be highly similar to an approved reference biologic according to the Food and Drug Administration (FDA), are coming on the market, but they do not yet offer much savings. The FDA has approved biosimilars to etanercept, infliximab and adalimumab.

“Prices for biosimilars are not nearly as aggressive as we had hoped: about 10–15% lower than the reference product,” says Sheila Arquette, RPH, executive director of the National Association of Specialty Pharmacists in Alexandria, Va. Some reference biologics manufacturers are increasing rebates to pharmacy benefit managers and large health insurance plans to keep their costs down, but this strategy may preclude them from including the biosimilar on their formularies. Rebates may not be passed along as savings to the patient at the point of sale, she says.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Practice Management Tagged With: Biologics, biosimilar, Compliance, cost, drug, generic, Healthcare, Medication, patient care, Rheumatic Disease, rheumatologist, TreatmentIssue: June 2017

You Might Also Like:
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
  • 8 Ways to Help Your Patients with Medication Costs

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)